For about a decade now, the big three medtech companies—Wipro GE Healthcare, Philips Healthcare and Siemens Healthineers—have desperately tried their luck in rural India. And had little success.

They’ve made repeated attempts to sell everything from ECGs to X-rays and infant warmers to the rural population.

So, when S Ganeshprasad, the then-director at GE, spotted Aravamudan Krishna Kumar, the then-managing director at Philips, at a radiology conference in 2015, he was curious about Philips’ latest attempt.

After pleasantries, Kumar told him, “Ganesh, our rural experiment failed. It’s so difficult, you know, to maintain. Business is not very predictable; somewhere it works, somewhere it doesn’t work.”

2010 onwards, all device makers adjusted and readjusted to the market’s needs, building brand-new products from the ground up. Low-cost ultrasounds, ECGs and infant warmers. But the target market didn’t make an easy switch. Philips, it appeared, was the latest casualty. Ganeshprasad’s heart skipped.

You see, GE was to announce its latest experiment that very day. It had a minority 26% stake in GenWorks Health Private Limited, an independent startup that would sell affordable GE devices to rural India, primarily for a commission. This would be the first such investment for the conglomerate. Ganeshprasad would helm GenWorks.

He had been with GE for 18 years, heading sales of ultrasounds, cardiology and other products. Under his tenure, the ultrasound business grew to $100 million in sales, with a 48% marketshare, making it among the most successful portfolios at GE. “Oh my god, I’m getting into it today!” Ganeshprasad recalled thinking last month at his office, which is in an IT park, a 15-minute drive from the GE campus in Bengaluru.

Following GE’s announcement of GenWorks, colleagues had crowded around Ganeshprasad at the conference, he recalled.

All of them had questions. “Why did you do this? You’re so successful!” “Why did you even do this man, c’mon!” “This is stupid, this is a risk you’re taking at this stage of your life. Now GE will just forget this, what will happen to you?”

Selling healthcare to rural Indians is a tough proposition, so medtech companies focus on urban residents. Today, a major portion of the revenue of many companies comes from selling to corporate hospitals and large diagnostic centres in metro cities. That’s unfortunate because most of India’s population—about 833 million people—live in the countryside and go to government or rural hospitals. Many do not have access to MRIs, CT scanners or even low-cost devices (or “boxes”, in industry parlance) such as ECGs. A whole market remains under tapped.

Indian challenge

MNCs realised in the late 90s that equipment sourced from the US does not work well in India. The dimensions, weight and the mobility parameters of these equipment were poor because they had to be fixed and used in one place, said Raghunath Subramanian at IIM Bangalore.


Gayathri Vaidyanathan

Gayathri writes on health, environment and science. She has reported and produced stories for the Washington Post, Discover, Nature, and the New York Times, amongst other publications. In her last assignment, she was the lead science writer for E&E News in Washington, D.C. E&E News is a news organisation focused on energy and the environment. Over the past decade, Gayathri has travelled across North America, Africa and Asia on long-form reporting projects. She has a master’s in journalism from Columbia University and a bachelor's in biochemistry from McMaster University in Ontario. At The Ken, Gayathri will write on healthcare, the pharmaceutical business and the environment. Based in Bengaluru, you can reach her at gayathri at the rate

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.